Compounds, compositions and methods for synthesis

US12428442B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12428442-B2
Application numberUS-202318316932-A
CountryUS
Kind codeB2
Filing dateMay 12, 2023
Priority dateJun 21, 2017
Publication dateSep 30, 2025
Grant dateSep 30, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides reagents and methods for chirally controlled preparation of oligonucleotides. In some embodiments, technologies of the present disclosure are particularly useful for constructing challenging internucleotidic linkages, providing high yields and stereoselectivity.

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having the structure of formula V-b: or a salt thereof, wherein: P L is P; is of such a structure that is a compound of formula I-e or a salt thereof: wherein: -L 8 -H is the —OH shown in formula I-e; t is 1; Ring A is an optionally substituted 6-membered ring having 0-4 heteroatoms; each of R 1 , R 3 , R 4 , and R 5 is independently —H, -L s -R, halogen, —CN, —NO 2 , -L s -Si(R) 3 , —OR, —SR, or —N(R) 2 ; R 6 is —H; —NHR 5 is —NR 5 R 6 shown in formula I-e; each L s is independently a covalent bond, or a bivalent, optionally substituted, linear or branched group selected from a C 1-30 aliphatic group and a C 1-30 heteroaliphatic group having 1-10 heteroatoms, wherein one or more methylene units are optionally and independently replaced by an optionally substituted group selected from C 1-6 alkylene, C 1-6 alkenylene, —C≡C—, a bivalent C 1 -C 6 heteroaliphatic group having 1-5 heteroatoms, —C(R′) 2 —, -Cy-, —O—, —S—, —S—S—, —N(R′)—, —C(O)—, —C(S)—, —C(NR′)—, —C(O)N(R′)—, —N(R′)C(O)N(R′)—, —N(R′)C(O)O—, —S(O)—, —S(O) 2 —, —S(O) 2 N(R′)—, —C(O)S—, —C(O)O—, —P(O)(OR′)—, —P(O)(SR′)—, —P(O)(R′)—, —P(O)(NR′)—, —P(S)(OR′)—, —P(S)(SR′)—, —P(S)(R′)—, —P(S)(NR′)—, —P(R′)—, —P(OR′)—, —P(SR′)—, —P(NR′)—, —P(OR′)[B(R′) 3 ]—, —OP(O)(OR′)O—, —OP(O)(SR′)O—, —OP(O)(R′)O—, —OP(O)(NR′)O—, —OP(OR′)O—, —OP(SR′)O—, —OP(NR′)O—, —OP(R′)O—, and —OP(OR′)[B(R′) 3 ]O—, and one or more carbon atoms are optionally and independently replaced with Cy L ; each -Cy- is independently an optionally substituted bivalent group selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; each Cy L is independently an optionally substituted tetravalent group selected from a C 3-20 cycloaliphatic ring, a C 6-20 aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms; each R′ is independently —R, —C(O)R, —C(O)OR, or —S(O) 2 R; BA is an optionally substituted group selected from a natural nucleobase moiety and a modified nucleobase moiety; each R s is independently —H, halogen, —CN, —N 3 , —NO, —NO 2 , -L s -R′, -L s -Si(R) 3 , -L s -OR′, -L s -SR′, -L s -N(R′) 2 , —O-L s -R′, —O-L s -Si(R) 3 , —O-L s -OR′, —O-L s -SR′, or —O-L s -N(R′) 2 ; Ring A s is wherein each of R 2s and R 4s is independently R s ; R 5s is R s ; each R is independently —H, or an optionally substituted group selected from C 1-30 aliphatic, C 1-30 heteroaliphatic having 1-10 heteroatoms, C 6-30 aryl, C 6-30 arylaliphatic, C 6-30 arylheteroaliphatic having 1-10 heteroatoms, 5-30 membered heteroaryl having 1-10 heteroatoms, and 3-30 membered heterocyclyl having 1-10 heteroatoms, or two R groups are optionally and independently taken together to form a covalent bond, or: two or more R groups on the same atom are optionally and independently taken together with the atom to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms; or two or more R groups on two or more atoms are optionally and independently taken together with their intervening atoms to form an optionally substituted, 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the intervening atoms, 0-10 heteroatoms. 2. The compound of claim 1 , wherein R 3 is —H. 3. The compound of claim 2 , wherein R 1 is optionally substituted C 1-6 aliphatic. 4. The compound of claim 3 , wherein R 1 is methyl. 5. The compound of claim 2 , wherein R 1 is optionally substituted phenyl. 6. The compound of claim 2 , wherein R 5 is optionally substituted C 1-6 aliphatic. 7. The compound of claim 3 , wherein R 5 is optionally substituted C 1-6 aliphatic. 8. The compound of claim 5 , wherein R 5 is optionally substituted C 1-6 aliphatic. 9. The compound of claim 6 , wherein R 5 is methyl. 10. The compound of claim 7 , wherein R 5 is methyl. 11. The compound of claim 8 , wherein R 5 is methyl. 12. The compound of claim 1 , wherein BA is an optionally substituted group which group is selected from and tautomeric forms thereof. 13. The compound of claim 12 , wherein R 2s is —H. 14. The compound of claim 12 , wherein R 2s is —F. 15. The compound of claim 12 , wherein R 2s is —OR, wherein R is optionally substituted C 1-6 aliphatic. 16. The compound of claim 12 , wherein R 2s is —OMe. 17. The compound of claim 12 , wherein R 2s is —MOE. 18. The compound of claim 12 , wherein Ring A s is optionally substituted 19. The compound of claim 1 , wherein the compound of formula I-e or a salt thereof. 20. The compound of claim 1 , wherein the compound of formula I-e or a salt thereof. 21. The compound of claim 1 , wherein the compound of formula I-e or a salt thereof.

Assignees

Inventors

Classifications

  • Pyrimidine radicals · CPC title

  • having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms · CPC title

  • Syntheses without formation of a Si-C bond · CPC title

  • comprising a heterocyclic ring · CPC title

  • by oxygen atoms · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12428442B2 cover?
The present disclosure, among other things, provides technologies for synthesis, including reagents and methods for stereoselective synthesis. In some embodiments, the present disclosure provides compounds useful as chiral auxiliaries. In some embodiments, the present disclosure provides reagents and methods for oligonucleotide synthesis. In some embodiments, the present disclosure provides rea…
Who is the assignee on this patent?
Wave Life Sciences Ltd
What technology area does this patent fall under?
Primary CPC classification C07H21/04. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Sep 30 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 12 related publications on this page (citations in our corpus or others sharing the same primary CPC).